Multiplex Assay Kit for Matrix Metalloproteinase 7 (MMP7) ,etc. by FLIA (Flow Luminescence Immunoassay) Equus caballus; Equine (Horse) Multiplex ELISA

MPSL1; MAT; PUMP-1; Matrilysin Uterine; Matrilysin; Matrin; Pump-1 Protease; Uterine Metalloproteinase

(Note: Up to 8-plex in one testing reaction)

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Multiplex Assay Kit for Matrix Metalloproteinase 7 (MMP7) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Matrix Metalloproteinase 7 (MMP7) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Matrix Metalloproteinase 7 (MMP7) ,etc. by FLIA (Flow Luminescence Immunoassay) Results demonstration
  • LMA102Eq.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Matrix Metalloproteinase 7 (MMP7) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Matrix Metalloproteinase 7 (MMP7) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 79-98 87
EDTA plasma(n=5) 92-101 96
heparin plasma(n=5) 79-94 85

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Matrix Metalloproteinase 7 (MMP7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Matrix Metalloproteinase 7 (MMP7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Matrix Metalloproteinase 7 (MMP7) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 82-105% 86-104% 83-101% 79-91%
EDTA plasma(n=5) 87-99% 90-98% 98-105% 91-105%
heparin plasma(n=5) 84-93% 97-105% 88-97% 90-97%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:MMP7) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

Multiplex Assay Kit for Matrix Metalloproteinase 7 (MMP7) ,etc. by FLIA (Flow Luminescence Immunoassay)

Test principle

Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.

Giveaways

Citations

  • A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelPubMed: 20649573
  • Upregulated Expression of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinases in BALB/c Mouse Brain Challenged with Japanese Encephalitis VirusPubmed: source
  • A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic ApproachesPlosone: Source
  • Analysis of the expression of nine secreted matrix metalloproteinases and their endogenous inhibitors in the brain of mice subjected to ischaemic strokePubmed:24671655
  • Estrogen-deficient osteoporosis enhances the recruitment and activity of osteoclasts by breast cancer cellsPubMed: 26254457
  • Circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during Japanese encephalitis virus infectionPubmed:26925446
  • Systematic phenotyping and correlation of biomarkers with lung function and histology in lung fibrosisPubmed:26993522
  • The MiR-495/Annexin A3/P53 Axis Inhibits the Invasion and EMT of Colorectal Cancer Cellspubmed:29224019
  • Thyroid disrupting effects and associated mechanisms of TCPP in GH3 cell line and zebrafish (Danio rerio) larva and adult10371/137708
  • Large-scale proteomics identifies MMP-7 as a sentinel of epithelial injury and of biliary atresia.pubmed:29167395
  • Diagnostic Accuracy of Serum Matrix Metalloproteinase‐7 for Biliary AtresiaPubmed: 30153340
  • Quantification of Serum Matrix Metallopeptide 7 Levels May Assist in the Diagnosis and Predict the Outcome for Patients with Biliary AtresiaPubmed: 30853207
  • Serum MMP-7 in the Diagnosis of Biliary AtresiaPubmed: 31604829
  • Human umbilical cord blood mononuclear cells protect against renal tubulointerstitial fibrosis in cisplatin-treated ratsPubmed: 31710895
  • The synthetic toxin biliatresone causes biliary atresia in micePubmed: 32681026
  • Interstitial Score and Concentrations of IL-4R¦Á, PAR-2, and MMP-7 in Bronchoalveolar Lavage Fluid Could Be Useful Markers for Distinguishing Idiopathic Interstitial?¡­33924683
  • A novel strategy to identify candidate diagnostic and prognostic biomarkers for gastric cancer34215253

Recommend products